|
Mr. Van Hulst was from 1999 to 2005 executive vice president at Puerto Rico-based MOVA Pharmaceutical Corporation, a contract manufacturer to the pharmaceutical industry that recently merged with Canadian-based Patheon (TSX:PTI). He began his career in 1968 at the multinational Dutch company Organon, which was subsequently acquired by AKZO, N.V., holding various positions of increasing responsibility at the company, including president of AKZO’s generic drug business from 1986 to 1989. From 1989 to 1999 Mr. Van Hulst successively owned and led two generic pharmaceutical companies, improving their operations and then selling them to a private equity group and a pharmaceutical company. He is currently a director of Protein Sciences Corporation, a privately-held biotechnology company based in Meriden, Connecticut which utilizes recombinant DNA technology to develop and manufacture modern protein-based vaccines, diagnostics and therapeutics. | 